Saizen® E-Device User Trial

Growth Disorders Clinical Trial

Official title:

User Trial on the Use in Common Practice of a New Electronic Auto-injector of Saizen®, the E-Device (Electronic Device), in Children Treated by Recombinant Human Growth Hormone Over a Period of 2 Months

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00450190
• Other study ID #: 26443
• Status: Completed
• Phase: Phase 3
• Start date: February 28, 2006
• Est. completion date: September 30, 2006

Study information

• Verified date: September 2017
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to evaluate the E-Device performances and handling on the use in common practice, by collecting the impressions of patients, nurses and the investigator on the graphic interface, the instructions manual, the E-Device training and the material itself.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 30, 2006
• Est. primary completion date: September 30, 2006
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients naïve to, or experienced with, Saizen® with growth disorders in registered indications (GHD, Turner's Syndrome, Chronic Renal Failure, patient born Small Gestational Age [SGA] according to the local SmPC)

2. Written informed consent must be obtained from the parent(s)/legal guardian(s) at the beginning of the study. Children able to understand the trial should personally sign and date the written informed consent

Exclusion Criteria:

1. Known hypersensitivity to somatropin or any of the excipients

2. Epiphyseal fusion

3. Active neoplasia (either newly diagnosed or recurrent)

4. History of intracranial hypertension with papilledema

5. Diabetes mellitus or history of significant glucose intolerance as defined by a fasting blood glucose > 116 mg/dL

6. Severe congenital malformations

7. Severe psychomotor retardation

8. Known hepatic disease as defined by elevated liver enzymes or total bilirubin (x 2 N)

9. Current congestive heart failure, untreated hypertension, serious chronic oedema of any cause

10. Chronic infectious disease

11. Previous or ongoing treatment with sex steroid therapy such as estrogens and testosterone

12. Previous or ongoing treatment with any therapy that may directly influence growth, including GH, GHRF and long duration corticosteroids therapy

13. Proliferative or preproliferative diabetic retinopathy

14. Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion

15. Precocious puberty

16. Severe associated pathology affecting growth such as malnutrition, malabsorption or bone dysplasia

17. Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment

18. Participation to any clinical study within the 30 days preceding study entry

19. Pregnancy

Related Conditions & MeSH terms

• Growth Disorders

Intervention

Device:
• Saizen® E-Device
Saizen® (recombinant human growth hormone [r-hGH]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck KGaA

References & Publications (1)

Tauber M, Payen C, Cartault A, Jouret B, Edouard T, Roger D. User trial of Easypod, an electronic autoinjector for growth hormone. Ann Endocrinol (Paris). 2008 Dec;69(6):511-6. doi: 10.1016/j.ando.2008.04.003. Epub 2008 Jun 26. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjects' Overall Impression After Using E-Device	Subjects' overall impression after using E-Device was measured on a scale ranging from 1 to 3, where 1 = bad, 2 = good, and 3 = very good. Number of subjects with response based on overall impression scale were presented.	2 Weeks
Primary	Usefulness and Reliability of E-Device Functions	Following functions were assessed: Display of remaining dose in cartridge, Display of last injection date and time, Automatic needle attachment, Audible and visual signals, Dose injected confirmation, Dose history, Customizable needle insertion speed, Customizable drug insertion speed, Customizable insertion depth, Teach me menu, On screen instructions, Customizable name and picture, Pre-programmed dose and Skin sensor. Usefulness and reliability of each of the E-Device functions was measured on a scale ranging from 1 to 3, where 1 = not useful, 2 = useful, and 3 = very useful. Number of subjects with response based on usefulness and reliability scale were presented.	2 Weeks
Secondary	Subjects' Feedback Immediately After Initial Training During Inclusion Visit	Subjects' feedback immediately after initial training on the handling and use of E-Device was assessed on scale ranging from 1 to 3, where 1 = difficult, 2 = easy, and 3 = very easy. Subjects were provided training on the following aspects: Cartridge loading, Needle attachment, Needle detachment, Injection process, Navigation in the menu, and Handling of the device. Number of subjects with response based on their feedback were presented.	Inclusion visit (Day 1)
Secondary	Nurse/Physician's Feedback After E-Device Set up During Inclusion Visit	Nurse/physician's feedback was assessed for E-Device setting up and Dose programming on inclusion visit using a scale ranging from 1 to 3, where 1 = difficult, 2 = easy, and 3 = very easy. Nurse/Physician's response for the number of subjects were presented.	Inclusion visit (Day 1)
Secondary	Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs)	An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A Serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect, AEs leading to discontinuation and AEs leading to death.	Day 1 up to Day 90

External Links

•   Full FDA approved prescribing information can be found here